- Home
- IBIO vs NXTC Comparison
IBIO vs NXTC Comparison
Compare IBIO & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBIO | NXTC |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.4M | 44.6M |
| IPO Year | 2009 | 2019 |
Fundamental Metrics
Financial Performance| Metric | IBIO | NXTC |
|---|---|---|
| Price | $2.39 | $12.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $4.75 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 1.1M | 28.6K |
| Earning Date | 05-20-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.08 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,378,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $0.23 |
| 52 Week High | $5.85 | $15.74 |
Technical Indicators
Market Signals| Indicator | IBIO | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 53.03 |
| Support Level | $2.02 | $10.73 |
| Resistance Level | $3.01 | $13.47 |
| Average True Range (ATR) | 0.25 | 1.13 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 12.50 | 56.51 |
Price Performance
Historical ComparisonAbout IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.